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Abstract
Background: A growing body of work implicates chemokines, in particular CXCL12 and its receptors, in the
progression and site-specific metastasis of various cancers, including breast cancer. Various agents have been used
to block the CXCL12-CXCR4 interaction as a means of inhibiting cancer metastasis. However, as a potent
chemotactic factor for leukocytes, CXCL12 also has the potential to enhance anti-cancer immunity. To further
elucidate its role in breast cancer progression, CXCL12 and its antagonist CXCL12(P2G) were overexpressed in the
syngeneic 4T1.2 mouse model of breast carcinoma.
Results: While expression of CXCL12(P2G) significantly inhibited metastasis, expression of wild-type CXCL12 potently
inhibited both metastasis and primary tumor growth. The effects of wild-type CXCL12 were attributed to an
immune response characterized by the induction of CD8
+ T cell activity, enhanced cell-mediated cytotoxicity,
increased numbers of CD11c
+ cells in the tumor-draining lymph nodes and reduced accumulation of myeloid-
derived suppressor cells in the spleen.
Conclusions: This study highlights the need to consider carefully therapeutic strategies that block CXCL12
signaling. Therapies that boost CXCL12 levels at the primary tumor site may prove more effective in the treatment
of metastatic breast cancer.
Background
CXCL12 is a highly pleiotropic chemokine, influencing a
variety of biological processes through interaction with
its receptors CXCR4 and CXCR7. It is particularly pro-
minent in the context of immune responses, acting as a
potent chemotactic factor for mature T cells and mono-
cytes [1], mature dendritic cells (DC) [2], natural killer
(NK) cells and NKT cells [3].
In a landmark study, CXCR4 was shown to be
expressed by various human breast cancer cells, and
metastasis of these cells in severe combined immunodefi-
cient (SCID) mice could be inhibited with neutralizing
CXCR4 antibodies [4]. Subsequent studies have demon-
strated CXCR4 expression in a variety of cancer cells and
tumors (reviewed in [5]). CXCL12 and its receptors are
not only involved in processes specific to metastasis;
many of their functions promote primary tumor growth.
CXCL12 can promote breast tumor cell survival and
proliferation, at least in immune deficient mice [6].
Further, it can induce production of matrix metallopro-
teinases [7], and promote invasion of breast cancer cells
in vitro [8]. CXCL12 is also an angiogenic chemokine
and CXCL12 secretion by fibroblasts co-implanted into
nude mice with breast carcinoma cells promotes vascu-
larization of the developing tumors [6].
A number of different agents have been used to block
the CXCL12-CXCR4 interaction as a means of inhibiting
metastasis. These include neutralizing anti-CXCR4 antibo-
dies [4], pharmacologic inhibitors such as AMD3100 [9]
and T140 [10], and small interfering RNAs directed
towards CXCR4 [8,9]. In this work, we sought to deter-
mine whether a modified form of CXCL12, CXCL12(P2G),
which acts as an antagonist of CXCR4 [11], is able to
block metastasis in the 4T1.2 orthotopic mouse model of
breast cancer. Concomitantly, we examined the effects of
exogenous wild-type CXCL12 expression on metastasis.
We found that CXCL12(P2G) was able to inhibit both
spontaneous and experimental metastasis, without affect-
ing primary tumor growth. In contrast, wild-type CXCL12
blocked both metastasis and primary tumor growth in a
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tumor immune response.
Results
Generation and in vitro characterization of CXCL12
construct-expressing 4T1.2 mammary carcinoma cell lines
To determine if antagonizing CXCR4 by means of the
CXCR4 antagonist CXCL12(P2G) would impact on growth
and metastasis of 4T1.2 tumors, 4T1.2 cells were trans-
fected with a DNA construct encoding CXCL12(P2G).
In addition, 4T1.2 cells were transfected with a construct
encoding wild-type CXCL12, to determine the effect of
wild-type CXCL12 on tumor growth and metastasis. As a
control, a DNA construct encoding a biologically inactive
form of CXCL12, CXCL12(Ala), in which the four cysteine
residues were mutated to alanine residues, was trans-
fected into 4T1.2 cells. The cell lines generated following
transfection of the wild-type CXCL12, CXCL12(P2G) and
CXCL12(Ala) constructs were labeled 4TX12, 4T12P2G
and 4T12Ala, respectively. Expression of the CXCL12
constructs was confirmed by RT-PCR (Additional File 1)
and ELISA (Fig. 1A). Neither CXCL12(P2G) nor CXCL12
expression significantly affected the growth of 4T1.2 cells
in vitro (Fig. 1B, C and Additional File 2).
The effects of CXCL12(P2G) and CXCL12 expression on
tumor growth and metastasis
In our initial experiments, we found that CXCL12(P2G)
significantly inhibited spontaneous metastasis of 4T1.2
tumors to the lungs of tumor-bearing mice (Fig. 2A),
without affecting primary tumor growth (Figs. 2B, C).
Migration of CXCL12(P2G)-expressing 4T12P2G cells to
the lungs was also inhibited when the tumor cells were
introduced directly into the circulation (Fig. 2D), sug-
gesting that CXCL12(P2G) interferes with steps of metas-
tasis that occur after metastatic cells have escaped from
the primary tumor. Wild-type CXCL12 similarly inhib-
ited both spontaneous and experimental metastasis, but
in contrast to CXCL12(P2G), CXCL12 concomitantly
inhibited primary tumor growth (Fig. 2). The inhibitory
effects of CXCL12 on primary tumor growth were con-
firmed in the EMT6.5 syngeneic mouse model of breast
cancer (Additional File 3). Neither CXCL12(P2G) nor
CXCL12 expression affected tumor angiogenesis (Fig. 3).
CXCL12 expression promotes an anti-tumor immune
response
The ability of wild-type CXCL12 to inhibit both primary
tumor growth and metastasis makes it a more attractive
candidate than the CXCR4 antagonist for incorporation
into therapeutic strategies for breast cancer. Thus, we
chose to investigate further this form of the chemokine
to determine how it might exert its effects. Since
Figure 1 In vitro characterization of transfected 4T1.2 cells.
A) Expression of CXCL12 constructs by transfected cell lines as
determined by CXCL12 ELISA. Note that detection of 4T12Ala
protein is likely to be hampered because of the disrupted tertiary
structure of the chemokine. Similar levels of expression of all three
constructs were detected by PCR (Additional File 1). B) Growth of
transfected 4T1.2 cell lines compared to wild-type 4T1.2 cells in
medium supplemented with 1% FCS, as determined by XTT
proliferation assay. Data points represent mean ± SEM of
determinations from 2 independent experiments. C) Tumorigenicity
of transfected 4T1.2 cells grown in semi-solid agar compared to
wild-type 4T1.2 cells. Bars represent mean ± SEM of determinations
from 3 experiments.
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cells in vitro, it seemed likely that inhibition of tumor
growth could be due to the effects of CXCL12 on the
host rather than on the tumor cells directly. Given that
CXCL12 induces responses in a variety of leukocytes,
we sought to determine whether CXCL12 was affecting
the anti-tumor immune response.
A variety of gene-targeted and cell subset-depleted mice
were used to characterize the immune response to 4T1.2
tumors. In SCID mice, the growth inhibition of CXCL12-
expressing 4TX12 tumors was completely lost (Fig. 4A, B).
Subsequent cell depletion experiments in immune compe-
tent mice revealed that CD8
+,b u tn o tC D 4
+ cells were
required for the anti-tumor effect (Fig. 4C, D), suggesting
that cytotoxic T cells play an important role in CXCL12-
mediated tumor inhibition. Accordingly, the in vitro cyto-
toxic response of effector cells derived from 4TX12
tumor-bearing mice was enh a n c e dc o m p a r e dt ot h a to f
control tumor-bearing mice (Fig. 5A). Moreover, the anti-
tumor effect of CXCL12 was reduced in pfp
-/- mice, which
lack the cytotoxic mediator perforin, and TRAIL
-/- mice
(Table 1). Since IFN-g production is another major func-
tion of effector CD8
+ Tc e l l s[ 1 2 ] ,w ea l s oa s s e s s e dt h e
growth of 4TX12 tumors in IFN-g
-/- mice. As shown in
Table 1, IFN-g is important for the inhibition of 4T1.2
tumor growth mediated by CXCL12.
Examination of the secondary lymphoid organs of
tumor-bearing mice revealed some significant differ-
ences. The tumor-draining lymph nodes (DLN) from
4TX12 tumor-bearing mice harbored a greater number
Figure 2 The effect of CXCL12 and CXCL12(P2G) expression on growth and metastasis of 4T1.2 tumors.A )E f f e c t so fC X C L 1 2 (P2G) and
CXCL12 expression on the formation of spontaneous lung metastases in 4T1.2 tumor-bearing mice. Balb/c mice were injected with 4T1.2,
4T12P2G or 4TX12 cells i.m.f.p.. On day 21, lungs were removed and surface lung metastases were counted under a dissecting microscope. Bars
represent the median. *, P < 0.05; ***, P < 0.001 (Kruskal-Wallis), n = 11-21 from two independent experiments. B) BALB/c mice were injected
with 4T1.2, 4T12Ala, 4T12P2G or 4TX12 cells i.m.f.p. and tumor growth was monitored using digital calipers. C) At the end of the experiment,
mice were killed and their tumors resected and weighed ***, P < 0.0001 (ANOVA), n = 12. Data points and bars represent mean ± SEM. D)
Effects of CXCL12(P2G) and CXCL12 expression in 4T1.2 cells on the formation of experimental lung metastases. BALB/c mice were injected
intravenously with 7.5 × 10
5 cells in PBS. After approximately 2 weeks, lungs were harvested and surface metastatic nodules were enumerated
under a dissecting microscope. Data points represent the number of surface metastatic nodules of individual mice. Bars represent the median.
**, P < 0.01 (Kruskal-Wallis).
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+ DC than those from controls (Fig. 5B-F), in
agreement with a previous study in colon carcinoma
[13]. In the spleen, we found that myeloid-derived sup-
pressor cells (MDSC), a population of Gr1
+CD11b
+
immature myeloid progenitors that have profound
immunosuppressive effects in malignant disease [14],
were significantly reduced in 4TX12 tumor-bearing mice
compared to control tumor-bearing mice (Fig. 5G-H).
Together these data indicate that the pro-immunogenic
effects of CXCL12 are two-fold: first it promotes the accu-
mulation of cells that activate the immune response, and
second, it limits the generation of cells with immunosup-
pressive effects.
Discussion
In this study we have shown that a novel antagonist of
CXCR4, a mutant form of the natural ligand, CXCL12,
is capable of blocking the spontaneous metastasis of
breast cancer cells from the primary tumor in an
orthotopic mouse model of breast cancer. Furthermore,
we have demonstrated that blockade of CXCR4 at meta-
static steps that follow entrance of malignant cells into
the circulation is sufficient to reduce metastasis,
although we cannot rule out a role for CXCR4 in escape
from the primary tumor. Several studies have reported
the inhibition of metastasis of human MDA-MB-231
breast cancer cells in SCID mice using anti-CXCR4 anti-
bodies [4,15], siRNA [8,16] or peptide antagonists of
CXCR4 [10,15]. Our data extend these findings by
demonstrating that blockade of CXCR4 inhibits both
spontaneous and experimental metastasis in a more bio-
logically relevant orthotopic model of breast cancer. Our
results are in agreement with those obtained in a similar
study by Smith et al [9] in which siRNA knockdown of
CXCR4 inhibited both spontaneous and experimental
metastasis. However, in that study, CXCR4 knockdown
was also found to inhibit primary tumor growth. We
found that blocking CXCR4 by expressing CXCL12(P2G)
Figure 3 The effect of CXCL12(P2G) and CXCL12 expression on tumor angiogenesis. Representative micrographs of blood vessels in
A) a 4T12Ala tumor, B) a 4T12P2G tumor and C) a 4TX12 tumor. Magnification: 100x. D) Quantitation of the area occupied by blood vessels. The
percentage area occupied by blood vessels per high power field was determined using ImageJ software (http://rsbweb.nih.gov/ij/). Bars
represent the mean ± SD, n = 5-12 individual mice.
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metastasis-specific effect of this antagonist.
In contrast to CXCL12(P2G), wild-type CXCL12 inhib-
ited both metastasis and primary tumor growth. It has
been demonstrated previously that that co-implantation
of tumor cells with fibroblasts expressing CXCL12
enhances tumor growth [6]. However, that study was
performed in T cell-deficient nude mice and thus our
findings in an immunocompetent mouse model are not
contradictory. Moreover, although Orimo et al found
that the enhanced tumor growth was in part dependent
on increased angiogenesis [6], we found that neither
expression of CXCL12 nor CXCL12(P2G) altered tumor
angiogenesis in our model. Similarly, Smith et al did not
see inhibition of angiogenesis when they knocked down
CXCR4 expression in 4T1 cells [9]. It has been shown
that 4T1 cells produce endogenous vascular endothelial
growth factor (VEGF) [17] but not CXCL12 (Fig. 1A
and Additional File 1). Thus it is not surprising that
CXCL12 and CXCL12(P2G) expression does not affect
angiogenesis in this model since the tumor cells are cap-
able of producing VEGF independently of CXCL12. The
anti-tumor effects of CXCL12 and anti-metastatic effects
of CXCL12(P2G) a r et h e r e f o r eu n l i k e l yt ob ear e s u l to f
reduced angiogenesis.
Further analysis of the anti-tumor effect of CXCL12
revealed that it was dependent on the presence of func-
tional CD8
+ T cells, in agreement with a previous study
that demonstrated the importance of CD8
+ T cells in
CXCL12-mediated growth inhibition of melanoma and
lung carcinoma [13]. However, our findings contrast with
those in a model of leukemia, in which CD4
+,b u tn o t
CD8
+, T cells were required [18] and the findings in a
fibrosarcoma model, where both T cell subsets were
Figure 4 Growth of 4TX12 tumors in immunodeficient and cell subset-depleted mice. A-B) SCID mice were injected i.m.f.p. with 1 × 10
5 cells.
Tumor volume (mean ± SEM; A) and final tumor weight (mean ± SEM; B) were measured (n = 5). C-D) BALB/c mice were injected i.m.f.p. with 1 × 10
5
cells and treated with anti-CD4, anti-CD8, control IgG or PBS as described in Materials and Methods. Data points represent mean tumor volume ± SEM
in mice depleted of (C) CD4
+ cells, n = 8, and (D) CD8
+ cells, n =6 ;* ,p < 0.05; ns, not significant compared to 4TX12 tumors in mice treated with
control IgG (t test).
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cytotoxicity against 4T1.2 tumors. BALB/c mice were injected i.m.f.p. with 1 × 10
5 cells. After approximately 5 weeks, effector cells were prepared
for use in a cytotoxicity assay as described in Materials and Methods. *, P < 0.05, significantly different from naïve effectors and effectors from
4T12Ala tumor-bearing mice (Kruskal-Wallis). B-F) CD11c
+ cell infiltration of tumor-draining lymph nodes. Cryostat sections from inguinal (B, D)
and axillary (C, E) draining lymph nodes 6 days post 4T12Ala (B, C) or 4TX12 (D, E) cell injection were stained with anti-CD11c antibody.
Magnification: 100×. F) CD11c
+ cells were enumerated in ten randomly selected high power fields per lymph node. Bars represent the mean
number (± SEM) of CD11c
+ cells per field. n = 3 mice (i.e. 6 lymph nodes) per group from two independent experiments. ***, p < 0.0001 (t test).
G-H) Accumulation of MDSC in spleens of tumor-bearing mice. BALB/c mice were injected i.m.f.p. with 1 × 10
5 cells. Spleens were resected 28
days later and the percentage (G) and the absolute numbers (H) of Gr1
+CD11b
+ splenocytes in tumor-bearing and control (naïve) mice was
determined by flow cytometry. Bars represent the mean ± SEM of duplicate determinations from 5 mice. ***, P < 0.0001 (t test).
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CXCL12 is able to induce different anti-tumor responses
depending on the tumor type.
In line with the requirement for CD8
+ Tc e l l s ,t h e
in vitro cytotoxic response of effector cells derived from
4TX12 tumor-bearing mice was enhanced compared to
that of control tumor-bearing mice. In support of this
finding, the anti-tumor effect of CXCL12 was reduced
in pfp
-/- mice and in TRAIL
-/- mice, suggesting that the
CD8
+ T cells exert their effects via the death receptor
pathway as well as the granule exocytosis pathway. IFN-
g was also found to be important for CXCL12-mediated
inhibition of 4T1.2 tumor growth which indicates that
CD8
+ T cells may exert not only direct cytotoxic func-
tion against tumor cells, but also indirect effects via
IFN-g-mediated activation of other effector cells.
Despite the requirement for functional CD8
+ Tc e l l s
for the tumor inhibitory effect of CXCL12, increased
infiltration of CXCL12-expressing tumors by T cells was
not observed (data not shown). However, the number of
dendritic cells in tumor-DLN was increased, in agree-
ment with a previous study in colon carcinoma [13].
Based on the observations discussed above, it seems
likely that CXCL12, while not increasing T cell infiltra-
tion of the tumor mass, acts to enhance T cell activation
by increasing the proportion of DC in the tumor-DLN.
Responsiveness to CXCL12 increases during the matura-
tion process of DC [2], and CXCR4 directly promotes
survival of DC, particularly those of a mature phenotype
[20]. The ability of CXCL12 to enhance the survival of
mature DC may be critical to the generation of suffi-
cient mature DC for priming of anti-tumor T cells and
may represent a key aspect of the anti-tumor response.
Although previous work by Zou et al [21] has shown
that CXCL12 expression by ovarian tumors promotes
the accumulation of immunosuppressive plasmacytoid
DCs, we did not observe this in our model. As discussed
above, CXCL12 can induce different responses depend-
ing on the tumor type. In addition, that study was per-
formed in human tissues expressing endogenous
CXCL12, in contrast to our study in which CXCL12
was overexpressed. The levels of CXCL12 at the tumor
site may determine the type of immune response gener-
ated, with lower levels promoting the accumulation of
immunosuppressive cells while higher levels recruit
immunoresponsive cells.
Another significant finding of this work was that
CXCL12 expression prevented the accumulation of
MDSC in the spleens of tumor-bearing mice. It has
been shown previously that mice bearing 4T1 tumors
have elevated levels of splenic MDSC, and that reduc-
tion of MDSC and resistance to metastatic disease
following removal of the primary tumor is dependent on
the presence of CD8
+ cells and IFN-g [17]. In our
model, it is possible that induction of CD8
+ T cell activ-
ity and IFN-g production by tumor-derived CXCL12
drives differentiation of MDSC into mature macro-
phages, abrogating their immunosuppressive effects.
Such a mechanism has been demonstrated in a model
of lung cancer [22].
Conclusions
Our studies demonstrate a significant anti-tumor role
for the CXCL12-CXCR4 axis in breast cancer progres-
sion. Early high-level CXCL12 expression at the tumor
site induces an anti-tumor response that depends on
CD8
+ T cells. CXCL12 expression results in enhanced
cell-mediated cytotoxicity towards tumor cells, increased
accumulation of CD11c
+ cells in the TDLN and reduced
accumulation of MDSC in the spleen. In addition, high
levels of CXCL12 in the tumor microenvironment may
disrupt the CXCR4 driven chemotactic response of
tumor cells towards CXCL12 expressing tissues such as
bone and lung. Although antagonism of CXCR4 is an
effective means of inhibiting tumor metastasis, our
results highlight the need to consider carefully the merit
of using such a strategy as a therapy for breast cancer.
It is noteworthy that a recent study has shown that
expression of CXCL12 in breast cancer tissues signifi-
cantly correlates with disease-free and overall survival
[23]. Thus therapies that incorporate boosting of
CXCL12 levels at the primary tumor site may be a more
Table 1 CXCL12-mediated inhibition of tumor growth in different strains of mice
Strain Experiment Day terminated Mean tumor weight (g) ± SEM (n) p value (t test) 4TX12 tumor weight as%
of control
4T12Ala 4TX12
Wild type 1 33 0.83 ± 0.06 (12) 0.20 ± 0.04 (12) ***, <0.0001 24.2
2 27 0.90 ± 0.13 (5) 0.21 ± 0.07 (6) ***, 0.0008 22.9
SCID 1 19 0.56 ± 0.11 (5) 0.60 ± 0.02 (5) ns, 0.7426 106.6
2 23 0.79 ± 0.08 (5) 0.76 ± 0.06 (5) ns, 0.7236 95.4
pfp
-/- 1 28 0.79 ± 0.10 (6) 0.49 ± 0.05 (6) *, 0.0232 61.4
TRAIL
-/- 1 28 0.78 ± 0.14 (7) 0.44 ± 0.03 (7) *, 0.0369 57.1
IFN-g
-/- 1 28 1.21 ± 0.17 (7) 0.64 ± 0.18 (7) *, 0.0403 52.9
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cing the anti-tumor immune response.
Methods
Antibodies and reagents
The following reagents were used in this study: rat anti-
CD31, biotinylated rat anti-Gr1, biotinylated hamster
anti-CD11c and PE-Cy7-conjugated rat anti-CD11b
(BD Biosciences, San Jose, CA); streptavidin-conjugated
phycoerythrin, fluorescein isothiocyanate and horserad-
ish peroxidase (HRP), HRP-conjugated donkey anti-rat
IgG and mouse gamma globulin (Rockland, Gilbertsville,
PA). Depleting anti-CD4, -CD8 and control IgG were
produced from the GK1.5, 53-6.72 and MAC4 hybrido-
mas, respectively.
Cells
The mouse breast cancer cell lines 4T1.2 (derived from
a spontaneous mammary carcinoma in a Balb/c mouse
[24]) and EMT6.5 (derived from EMT6 [25]) were cul-
tured in Alpha MEM and DMEM (Invitrogen, Carlsbad,
CA), respectively. Media were supplemented with 10%
fetal calf serum and 1% penicillin/gentamycin solution
("complete media”).
CXCL12 DNA constructs
cDNAs encoding wild-type mouse CXCL12, CXCL12
(P2G) (a CXCR4 antagonist in which the second proline
residue of wild-type CXCL12 is mutated to glycine) and
CXCL12(Ala) (a putative inactive form of CXCL12 in
which the mutations Cys9Ala and Cys11Ala disrupt the
tertiary structure of the molecule) with 6His carboxyl
tags were cloned into the pEF-IRES-puro6 vector (a gift
from Dr Dan Peet, University of Adelaide).
Transfections
The 4T1.2 cell line was transfected by electroporation.
Clones of stably transfected cells (selected with puromy-
cin) were obtained by limiting dilution. Equal numbers
of cells from each of the five highest secreting clones
were pooled for further experiments. Expression of the
CXCL12 protein was confirmed by ELISA (Fig. 1A).
Measurement of CXCL12 construct mRNA expression
Total cell RNA was extracted using TRIzol® reagent (Invi-
trogen) according to the manufacturer’s instructions and
treated with RNase-free DNase (1 U/μl; Promega, Madi-
son, WI). A total of 5 DNase-treated RNA was reverse
transcribed using random hexamers (Promega) and the
reverse-transcriptase Superscript III (200 U/μl; Invitrogen),
as directed by the manufacturer. The cDNA obtained was
treated with DNase-free RNase A (10 mg/ml; Sigma, St
Louis, MO) for 1 hour at 37°C, and 1.25μl was used as
template in subsequent PCR reactions. The sequences of
the primers (synthesised at Geneworks, Adelaide, Austra-
lia) used for PCR amplification were mCXCL12 F: 5′-
GGAATTCGCCACCATGGACGCCAAGGTCGTCG-3′,
mCXCL12 R: 5′-GACTAGTTCAGTGATGGTGATGG
TGGTGCATCTTGAGCCTC-3′, mGAPDH F: 5′-TCCTT
GGAGGCCATGTAGGCCAT-3′ and mGAPDH R:
5′-TGATGACATCAAGAAGGTGGTGAAG-3′.T h e
reaction was carried out in a final volume of 25 μla n d
contained 5 μl F primer (5 μM), 5 l R primer (5 μM), 2.5 l
10 × Mg
2+-free EXT buffer and 1.25 l MgCl2 (50 μM), 1 l
dNTPs (10 μM), 0.25 l DyNAzyme EXT polymerase and
1.25 μl of template cDNA. The reaction was carried out
on a Programmable Thermal Controller under the follow-
ing conditions: 94°C for 2 minutes, then 35 cycles of 94°C
for 30 seconds, 52°C for 45 seconds and 72°C for 1 minute,
followed by a final extension step of 72°C for 10 minutes.
Fragments were visualized by electrophoresis on a 2%
agarose gel.
Measurement of secreted CXCL12 protein
Cell culture supernatants were collected from 5 × 10
6
cells cultured for 3 days and protease inhibitor cocktail
(Sigma) was added at a 1:200 dilution. An ELISA plate
(Costar, Corning, NY) coated overnight with 2 g/ml
anti-CXCL12 capture antibody (R&D Systems, Minnea-
polis, MN) was blocked with PBS containing 1% BSA
(Sigma) and 5% sucrose before the addition of the cul-
ture supernatants. Biotinylated anti-CXCL12 antibody
(R&D Systems) at 200 ng/ml followed by streptavidin-
HRP (Rockland) diluted 1:20000 were used to detect
bound CXCL12. Colorimetric quantitation was per-
formed using an o-phenylenediamine kit (Sigma) as per
the manufacturer’s instructions and absorbance was
measured at 490 nm.
In vitro proliferation assay
Cells (2.5 × 10
3/ml) were cultured in medium supple-
mented with 0.1%, 1% and 10% fetal calf serum for up
t o7d a y s .A td a y s0 ,2 ,5a n d7 ,s o d i u m3 ′-[1-(phenyla-
minocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro)
benzene sulfonic acid hydrate (XTT; Sigma) was used to
determine the relative number of viable cells per well
according to the manufacturer’s instructions.
Soft agar cloning
Iscove’s Modified Dulbecco’s Medium (IMDM; Invitro-
gen) was prepared containing 10% FCS, penicillin/genta-
mycin/Fungizone (Invitrogen) and Bacto Agar (BD
Diagnostic Systems, Sparks, MD). The wells of a 6-well
plate were coated with 1 ml IMDM + 0.7% Agar, which
was then allowed to set. A suspension of 1 × 10
3 cells in
1 ml IMDM + 0.3% agar was overlaid into the wells and
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bated at 37°C in 5% CO2 for 10 days and colonies
formed were counted under a dissecting microscope.
Tumor growth
Female 6-8 week old BALB/c mice were bred and main-
tained at the University of Adelaide Animal Facility.
SCID mice were obtained from the Animal Resources
Centre (Canning Vale, WA, Australia). TRAIL
-/-,p f p
-/-
and IFN-g
-/- mice on the BALB/c background (back-
crossed at least 10 generations) were bred at the Peter
MacCallum Cancer Centre [26]. Tumor cells (1 × 10
5
in 10 μl PBS) were injected into the fourth mammary
fat pad (i.m.f.p.). Tumor dimensions were determined
with digital calipers and volume calculated using the
equation width
2 × length/2. For depletion experiments,
mice also received 100 μg of depleting antibody by
intraperitoneal injection the day before, on the day of
receiving cells and weekly thereafter. Depletion of cell
subsets was confirmed by flow cytometric analysis of
splenocytes.
Measurement of metastasis
For measurement of spontaneous metastasis, tumor cells
(1 × 10
5 in 10 μl PBS) were injected into the fourth
mammary fat pad. Approximately 4 weeks later, mice
were killed and their lungs were inflated with PBS con-
taining 85% India ink, then fixed in 4% formaldehyde.
Surface lung metastases were counted under a dissecting
microscope. For measurement of experimental metasta-
sis, 7.5 × 10
5 cells in PBS were injected into the tail
vein. After approximately 2 weeks, lungs were harvested
and fixed in 4% formaldehyde. Surface lung metastases
were counted under a dissecting microscope.
Cytotoxicity assay
Mice received 1 × 10
5 cells by mammary fat pad injec-
tion. After 5 weeks, spleens and axillary lymph nodes
from each mouse were harvested as a source of effector
cells. Target 4T1.2 cells were labeled with 0.2 μMc a l -
cein AM (Invitrogen), plated in complete RPMI at 2.5 ×
10
4 cells/well in a 96-well plate and allowed to adhere 3
hours at 37°C. Effector cells (depleted of red blood cells)
were then added at the indicated concentrations. Plates
w e r ei n c u b a t e da t3 7 ° Ci n5 %C O 2 f o rf o u rd a y s .N o n -
adherent cells were removed and fluorescence of the
remaining cells was measured on a Molecular Imager
FX (BioRad Laboratories, Hercules, CA). Percentage
cytotoxicity was calculated as 100-(target fluorescence/
target only fluorescence × 100).
Immunohistochemistry
Cryostat sections were fixed in 60% acetone/40%
methanol for 10 minutes. Slides were rehydrated in
phosphate buffered saline (PBS), and endogenous per-
oxidase activity was blocked with 0.3% hydrogen per-
oxide for 10 minutes. Sections were blocked with 100
μg/ml mouse gamma globulin for 30 minutes. Sections
were incubated with primary antibody or isotype con-
trol for 2 hrs in a humidified chamber at room tem-
perature, then with HRP-conjugated secondary
antibody (for unconjugated primary antibody) or strep-
tavidin-HRP (for biotinylated primary antibody) for
1 hr. Bound antibody was detected with 3,3′-diamino-
benzidine (DAKO, NSW, Australia). Sections were
counterstained with hematoxylin.
Flow cytometry
Cells in PBS/1% BSA/0.04% sodium azide (PBA) were
blocked with 20 μg/ml mouse gamma globulin for
20 minutes, then incubated with primary antibodies or
isotype-matched controls for 30 minutes. Primary anti-
bodies were detected with streptavidin-fluorochrome
conjugate and LIVE/DEAD stain (Invitrogen) was used
to distinguish non-viable cells.
Statistical analysis
Statistical analysis was performed using GraphPad Instat
version 5.02 (GraphPad Software, http://www.graphpad.
com).
Additional material
Additional file 1: CXCL12 construct expression in transfected 4T1.2
cells. RNA from each of the cell lines derived from the pooled clones
was reverse-transcribed and subjected to PCR. (A) CXCL12. M: DNA size
markers, lane 1: 4T1.2, lane 2: 4T12Ala, lane 3: 4TX12, lane 4: 4T12P2G,
lane 5: positive control CXCL12::pEF-IRES-puro6 plasmid, lane 6: negative
control (no template in PCR reaction). (B) GAPDH. M: DNA size markers,
lane 1: 4T1.2, lane 2: 4T12Ala, lane 3: 4TX12, lane 4: 4T12P2G, lane 5:
negative control (no reverse transcriptase), lane 6: negative control (no
template in reverse transcription reaction), lane 7: negative control (no
template in PCR reaction).
Additional file 2: The effect of CXCL12 expression on in vitro
proliferation of 4T1.2 cells in complete medium and serum-reduced
medium. Growth of transfected 4T1.2 cell lines as determined by XTT
proliferation assay compared to wild-type 4T1.2 cells. (A) Cells grown in
medium supplemented with 0.1% FCS. (B) Cells grown in medium
supplemented with 10% FCS. Data points represent mean ± SEM of
determinations from 2 independent experiments.
Additional file 3: The effect of CXCL12 expression on growth of
EMT6.5 tumors. BALB/c mice were injected with EMTX12 or EMT12Ala
cells i.m.f.p. and tumor volume was monitored (A). At the end of the
experiment, mice were killed and their tumors resected and weighed (B).
**, P < 0.005 (t test), n = 10. Data points and bars represent mean ±
SEM.
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